Equibles does not estimate personal net worth.
Get an email with a short summary when Maravai Lifesciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get MRVI alertsKevin Herde is recorded as CFO at Maravai Lifesciences Holdings, Inc. (MRVI). The newest filing on record that lists Kevin Herde as CFO at Maravai Lifesciences Holdings, Inc. (MRVI) is dated April 24, 2026. The proxy statement of Maravai Lifesciences Holdings, Inc. reports total compensation of $1,730,738 for Kevin Herde in fiscal 2025, including a base salary of $247,771. Disclosed compensation is on record for 5 fiscal years. Kevin Herde has spoken on 18 earnings calls across 1 company, most recently for Maravai Lifesciences Holdings, Inc. on May 12, 2025. Maravai Lifesciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Maravai Lifesciences Holdings, Inc. includes Bernd Brust (CEO and Board Member), William "Trey" Martin, III (CEO and Board Member), William E. Martin III (CEO) and 7 others.
“As mentioned, I will summarize our financial results for Q1 and then discuss our reaffirmed financial expectations for the full year and leave in some prepared remarks as it relates to some of our actions that we believe help mitigate risk related to global tariffs and trade economics.”
“We're holding this call later than we have in the past and appreciate your patience as we work to close out our 2024 audit and complete our 10-K filing. Let me walk through the items that caused the delay in the outcome of each.”
“Starting on Slide 14, our Q3 2024 revenues were $65 million, slightly below our expectations. Both business segments fell short, with the NAP segment affected by reduced demand for CleanCap in both RUO and GMP areas and a delay requested by a customer on a preclinical program build.”
“I want to acknowledge the hard work of our team in generating over $73 million in revenues for the quarter, as well as the various operational and R&D achievements that highlight our employees' dedication.”
“Echoing Trey's remarks, we are pleased with the top line performance in the quarter and excited about the business accomplishments that are laying a solid foundation for our future.”
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Maravai Lifesciences Holdings, Inc. (MRVI) | Former Chief Financial Officer | $247,771 | $1,730,738 |
| 2024 | Maravai Lifesciences Holdings, Inc. (MRVI) | Chief Financial Officer | $489,346 | $2,339,364 |
| 2023 | Maravai Lifesciences Holdings, Inc. (MRVI) | Chief Financial Officer | $472,791 | $2,793,002 |
| 2022 | Maravai Lifesciences Holdings, Inc. (MRVI) | Chief Financial Officer | $448,431 | $1,741,482 |
| 2021 | Maravai Lifesciences Holdings, Inc. (MRVI) | Chief Financial Officer | $412,788 | $841,598 |
